Beneficial effects of synthetic KL4 surfactant in experimental lung transplantation

European Respiratory Journal

Volumn 37, Issue 4, 2011, Pages 925-932

  Saenz A ^a   Alvarez L ^a   Santos, M ^a   Lopez Sanchez A ^a   Castillo Olivares, J L ^a   Varela, A ^a   Segal, R ^b   Casals, C ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Discovery Laboratories Inc   (United States)

Author keywords

C reactive protein; Inflammation; Ischaemia reperfusion injury; Lipid peroxidation; Lung surfactant; Protein carbonyls

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; LIPID PEROXIDE; LYSYLLEUCYLLEUCYLLEUCYLLEUCYLLYSYLLEUCYLLEUCYLLEUCYLLEUCYLLYSYLLEUCYLLEUCYLLEUCYLLEUCYLLYSYLLEUCYLLEUCYLLEUCYLLEUCYLLYSINE; PHOSPHOLIPID; SURFACTANT PROTEIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ISCHEMIA; LUNG ALVEOLUS OXYGEN TENSION; LUNG INJURY; LUNG LAVAGE; LUNG TRANSPLANTATION; NONHUMAN; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; REPERFUSION INJURY;

ADSORPTION; ANIMALS; BRONCHOALVEOLAR LAVAGE; C-REACTIVE PROTEIN; CARBON; INFLAMMATION; LIPID PEROXIDATION; LUNG; LUNG TRANSPLANTATION; OXYGEN; PEPTIDES; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; REPERFUSION INJURY; SURFACE PROPERTIES; SWINE;

EID: 79551602342     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00020810     Document Type: Article

References (38)

1. Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6: 39-46.
2. De Perrot M, Liu M, Waddell TK, et al. Ischemia - reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167: 490-511.
3. Veldhuizen RA, Lee J, Sandler D, et al. Alterations in pulmonary surfactant composition and activity after experimental lung transplantation. Am Rev Respir Dis 1993; 148: 208-215. (Pubitemid 23187243)
4. Erasmus ME, Petersen AH, Oetomo SB, et al. The function of surfactant is impaired during the reimplantation response in rat lung transplants. J Heart Lung Transplant 1994; 13: 791-802. (Pubitemid 24310426)
5. Casals C, Varela A, Ruano ML, et al. Increase of C-reactive protein and decrease of surfactant protein A in surfactant after lung transplantation. Am J Respir Crit Care Med 1998; 157: 43-49. (Pubitemid 28071260)
6. Hohlfeld JM, Tiryaki E, Hamm H, et al. Pulmonary surfactant activity is impaired in lung transplant recipients. Am J Respir Crit Care Med 1998; 158: 706-712. (Pubitemid 28449430)
7. Valiño F, Casals C, Guerrero R, et al. Inhaled nitric oxide affects endogenous surfactant in experimental lung transplantation. Transplantation 2004; 77: 812-818. (Pubitemid 38436816)
8. Novick RJ, MacDonald J, Veldhuizen RA, et al. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med 1996; 154: 98-104. (Pubitemid 26255773)
9. Erasmus ME, Hofstede GJ, Petersen AH, et al. Effects of early surfactant treatment persisting for one week after lung transplantation in rats. Am J Respir Crit Care Med 1997; 156: 567-572. (Pubitemid 27351996)
10. Hausen B, Rohde R, Hewitt CW, et al. Exogenous surfactant treatment before and after sixteen hours of ischemia in experimental lung transplantation. J Thorac Cardiovasc Surg 1997; 113: 1050-1058. (Pubitemid 27271110)
11. Erasmus ME, Hofstede GJ, Petersen AH, et al. SP-A-enriched surfactant for treatment of rat lung transplants with SP-A deficiency after storage and reperfusion. Transplantation 2002; 73: 348-352. (Pubitemid 34174282)
12. Friedrich I, Borgermann J, Splittgerber FH, et al. Bronchoscopic surfactant administration preserves gas exchange and pulmonary compliance after single lung transplantation in dogs. J Thorac Cardiovasc Surg 2004; 127: 335-343. (Pubitemid 38176636)
13. Gunther A, Balser M, Schmidt R, et al. Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. J Thorac Cardiovasc Surg 2004; 127: 344-354. (Pubitemid 38176637)
14. Kermeen FD, McNeil KD, Fraser JF, et al. Resolution of severe ischemia - reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007; 26: 850-856. (Pubitemid 47199076)
15. Struber M, Hirt SW, Cremer J, et al. Surfactant replacement in reperfusion injury after clinical lung transplantation. Intensive Care Med 1999; 25: 862-864. (Pubitemid 29410658)
16. Struber M, Fischer S, Niedermeyer J, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007; 133: 1620-1625. (Pubitemid 46802578)
17. Amital A, Shitrit D, Raviv Y, et al. The use of surfactant in lung transplantation. Transplantation 2008; 86: 1554-1559.
18. Amital A, Shitrit D, Raviv Y, et al. Surfactant as salvage therapy in life threatening primary graft dysfunction in lung transplantation. Eur J Cardiothorac Surg 2009; 35: 299-303.
19. Zuo YY, Veldhuizen RA, Neumann AW, et al. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochim Biophys Acta 2008; 1778: 1947-1977.
20. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991; 254: 566-568. (Pubitemid 21917374)
21. Cochrane CG. Pulmonary surfactant in allergic inflammation: new insights into the molecular mechanisms of surfactant function. Am J Physiol Lung Cell Mol Physiol 2005; 288: L608-L609. (Pubitemid 40404126)
22. Moya F, Sinha S, Gadzinowski J, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018-1029.
23. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030-1038.
24. Institute of Animal Resources. Guide for the Care and Use of Laboratory Animals. Washington, National Academy Press, 1996.
25. Levine RL, Williams JA, Stadtman ER, et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233: 346-357.
26. Casals C, Arias-Diaz J, Valino F, et al. Surfactant strengthens the inhibitory effect of C-reactive protein on human lung macrophage cytokine release. Am J Physiol Lung Cell Mol Physiol 2003; 284: L466-L472. (Pubitemid 36231724)
27. Gay C, Collins J, Gebicki JM. Hydroperoxide assay with the ferricxylenol orange complex. Anal Biochem 1999; 273: 149-155. (Pubitemid 29430657)
28. Li JJ, Sanders RL, McAdam KP, et al. Impact of C-reactive protein (CRP) on surfactant function. J Trauma 1989; 29: 1690-1697. (Pubitemid 20024880)
29. Sáenz A, López-Sánchez A, Mojica-Lázaro J, et al. Fluidizing effects of C-reactive protein on lung surfactant membranes: protective role of surfactant protein A. FASEB J 2010; 24: 3662-3673.
30. Rodriguez-Capote K, Manzanares D, Haines T, et al. Reactive oxygen species inactivation of surfactant involves structural and functional alterations to surfactant proteins SP-B and SP-C. Biophys J 2006; 90: 2808-2821.
31. Ahuja A, Oh N, Chao W, et al. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant. Am J Respir Cell Mol Biol 1996; 14: 496-503. (Pubitemid 126440519)
32. Tonks A, Parton J, Tonks AJ, et al. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1070-L1080. (Pubitemid 40695432)
33. Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133: 235-249. (Pubitemid 351512299)
34. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996; 156: 4815-4820. (Pubitemid 26174467)
35. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001; 69: 1747-1754. (Pubitemid 32187634)
36. Ramage L, Proudfoot L, Guy K. Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles. Inhal Toxicol 2004; 16: 607-613. (Pubitemid 38988742)
37. Zhu Y, Miller TL, Chidekel A, et al. KL4-surfactant (Lucinactant) protects human airway epithelium from hyperoxia. Pediatr Res 2008; 64: 154-158.
38. Sáenz A, Canadas O, Bagatolli LA, et al. Effect of surfactant protein A on the physical properties and surface activity of KL4-surfactant. Biophys J 2007; 92: 482-492. (Pubitemid 46145781)